Phenotypes associated with this allele

• Allele Symbol: Trp53^tm3.1Glo
• Allele Name: targeted mutation 3.1, Guillermina Lozano
• Allele ID: MGI:3528279
• Summary: 14 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Trp53^tm3.1Glo/Trp53^tm3.1Glo	B6.129S7-Trp53^tm3.1Glo	MGI:3722620
ht2	Trp53^tm3.1Glo/Trp53^+	B6.129S7-Trp53^tm3.1Glo	MGI:3576493
ht3	Trp53^tm1Tyj/Trp53^tm3.1Glo	involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6	MGI:3722619
ht4	Trp53^tm3.1Glo/Trp53^tm4Glo	involves: 129S7/SvEvBrd * C57BL/6	MGI:5000508
cn5	Trp53^tm3.1Glo/Trp53^tm4Glo Tg(CAG-cre/Esr1*)5Amc/0	involves: 129S7/SvEvBrd * C57BL/6 * CBA	MGI:5000509
cx6	Pml^tm1Ppp/Pml^+ Trp53^tm3.1Glo/Trp53^tm3.1Glo	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo	MGI:7485800
cx7	Pml^tm1Ppp/Pml^tm1Ppp Trp53^tm3.1Glo/Trp53^+	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo	MGI:7485838
cx8	Pml^tm1Ppp/Pml^+ Trp53^tm3.1Glo/Trp53^+	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo	MGI:7485831
cx9	Pml^tm1Ppp/Pml^tm1Ppp Trp53^tm3.1Glo/Trp53^tm3.1Glo	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo	MGI:7485803
cx10	Mdm2^tm3.1Glo/Mdm2^tm3.1Glo Trp53^tm3.1Glo/Trp53^+	B6.129S-Mdm2^tm3.1Glo Trp53^tm3.1Glo	MGI:4835498
cx11	Mdm2^tm4.1Glo/Mdm2^tm4.1Glo Trp53^tm3.1Glo/Trp53^+	B6.129S-Mdm2^tm4.1Glo Trp53^tm3.1Glo	MGI:4835500
cx12	Mdm4^tm3.1Glo/Mdm4^tm3.1Glo Trp53^tm3.1Glo/Trp53^tm3.1Glo	involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N	MGI:5142303
cx13	Mdm2^tm1Glo/Mdm2^tm1Glo Trp53^tm3.1Glo/Trp53^tm4Glo	involves: 129S7/SvEvBrd * C57BL/6	MGI:5000504
cx14	Mdm2^tm1Glo/Mdm2^tm1Glo Trp53^tm3.1Glo/Trp53^+	involves: 129S7/SvEvBrd * C57BL/6	MGI:3576494

Genotype
MGI:3722620

hm1

• Allelic Composition: Trp53^tm3.1Glo/Trp53^tm3.1Glo
• Genetic Background: B6.129S7-Trp53^tm3.1Glo

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:95318 , J:317504 )

• homozygous mutants die between 50 to 250 days after birth, however this survival curve is no different from homozygous null Trp53 mice (J:95318)

♂ • mean survival of male mice is 164.5 days (J:317504)

prenatal lethality, incomplete penetrance ( J:317504 )

♀ • only 11% of females are born, indicating a severe reduction in female survival

neoplasm

increased lymphoma incidence ( J:95318 )

• 70% of mice develop lymphomas

increased sarcoma incidence ( J:95318 )

• 29% of mice develop sarcomas

homeostasis/metabolism

increased DNA replication ( J:95318 )

• DNA synthesis rates for mouse fibroblast cells continue to synthesize DNA after 10 days in culture whereas MEFs from a Trp53^tm1Tyj homozygote are quiescent at day 6

cellular

increased fibroblast proliferation ( J:95318 )

• at day 4 of culture, mouse embryonic fibroblast (MEF)cells reach a higher saturation concentration than do MEFs from a Trp53^tm1Tyj homozygote

increased DNA replication ( J:95318 )

• DNA synthesis rates for mouse fibroblast cells continue to synthesize DNA after 10 days in culture whereas MEFs from a Trp53^tm1Tyj homozygote are quiescent at day 6

Genotype
MGI:3576493

ht2

• Allelic Composition: Trp53^tm3.1Glo/Trp53⁺
• Genetic Background: B6.129S7-Trp53^tm3.1Glo

mortality/aging

premature death ( J:95318 , J:317504 )

• heterozygous mutants die between 150 to 750 days after birth, however this survival curve is no different from heterozygous Trp53 mice (J:95318)

• median survival for the combined population of both males and females is 499 days i.e., similar to that of mice heterozygous for both Trp53 ^tm3.1Glo and Pml^tm1Ppp (504 days) (J:317504)

• median survival is 515 days for male mice and 463 days for female mice (J:317504)

neoplasm

increased metastatic potential ( J:95318 )

• the osteosarcomas and carcinomas of heterozygous mutants metastasized when compared to heterozygous Trp53^tm1Tyj mice

increased lymphoma incidence ( J:95318 , J:317504 )

• 31.5% of heterozygous mutants developed lymphomas (J:95318)

• 52% of mice develop lymphomas (when expressed as a % of tumor type); 13% of mice develop two tumor types, lymphomas and sarcomas (J:317504)

• 44% of mice exhibit lymphomas when tumor incidence is evaluated per mouse, including those that succumb to EMH, and expressed as a % disease/total number of mice (J:317504)

• when tumors are segregated by gender, 50% of males and 38% of females exhibit lymphomas (expressed as a % disease/total number of mice) (J:317504)

increased T cell derived lymphoma incidence ( J:317504 )

• only ~10% of lymphoid tumors are T-cell lymphomas

increased B cell derived lymphoma incidence ( J:317504 )

• immunophenotyping of lymphocytes from terminally resected tumors showed that ~90% of lymphoid tumors are B-cell lymphomas

increased carcinoma incidence ( J:95318 , J:317504 , J:317504 )

• 15.5% of heterozygous mutants developed carcinomas, which are rare in homozygotes (J:95318)

• 4% of mice develop carcinomas (whether expressed as a % of tumor type or as a % disease/total number of mice) (J:317504)

♀ • when tumors are segregated by gender, 0% of males and 8% of females exhibit carcinomas (expressed as a % disease/total number of mice) (J:317504)

increased sarcoma incidence ( J:95318 , J:317504 )

• 53% of heterozygous mutants developed sarcomas (J:95318)

• 43% of mice develop sarcomas (when expressed as a % of tumor type); 13% of mice develop two tumor types, lymphomas and sarcomas (J:317504)

• 37% of mice exhibit sarcomas (when expressed as a % disease/total number of mice) (J:317504)

• when tumors are segregated by gender, 14% of males and 8% of females exhibit soft-tissue sarcomas (expressed as a % disease/total number of mice) (J:317504)

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by gender, 14% of males and 38% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

cellular

abnormal cell cycle ( J:95318 )

• higher DNA synthesis in MEFs with cells continuing to synthesize DNA between days 6 and 10 of culture compared to wildtype or heterozygous or homozygous Trp53^tm1Tyj MEFs which reached a quiescent state at day 6 and did not reenter the cell cycle

decreased cellular sensitivity to gamma-irradiation ( J:95318 )

• irradiated E13.5 heterozygous embryos showed no evidence of apoptosis in the hypothalamus compared to wildtype and heterozygous Trp53^tm1Tyj mutants that showed a high number of apoptotic cells

increased fibroblast proliferation ( J:95318 )

• MEFs initially did not show any significant differences in growth rate but by day 4, grew more rapidly than wildtype or heterozygous or homozygous null Trp53^tm1Tyj MEFs and reached a much higher saturation density

hematopoietic system

increased T cell derived lymphoma incidence ( J:317504 )

• only ~10% of lymphoid tumors are T-cell lymphomas

hepatosplenomegaly ( J:317504 )

• mice exhibit pronounced hepatosplenomegaly

extramedullary hematopoiesis ( J:317504 )

• 41% mice exhibit extramedullary hematopoiesis (EMH), with no histological evidence of transformation to acute leukemia

• EMH is associated with peripheral blood leukocytosis and macrocytic anemia, indicative of a myeloproliferative/myelodysplastic overlap

• when segregated by gender, 43% of males and 31% of females exhibit EMH

macrocytic anemia ( J:317504 )

• mice with EMH exhibit macrocytic anemia

increased leukocyte cell number ( J:317504 )

• mice with EMH exhibit peripheral blood leukocytosis

immune system

increased T cell derived lymphoma incidence ( J:317504 )

• only ~10% of lymphoid tumors are T-cell lymphomas

hepatosplenomegaly ( J:317504 )

• mice exhibit pronounced hepatosplenomegaly

increased leukocyte cell number ( J:317504 )

• mice with EMH exhibit peripheral blood leukocytosis

liver/biliary system

hepatosplenomegaly ( J:317504 )

• mice exhibit pronounced hepatosplenomegaly

growth/size/body

decreased body weight ( J:317504 )

• average body weight is significantly lower than that in C57BL/6 wild-type controls

hepatosplenomegaly ( J:317504 )

• mice exhibit pronounced hepatosplenomegaly

skeleton

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by gender, 14% of males and 38% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:317504 )

• only ~10% of lymphoid tumors are T-cell lymphomas

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Li-Fraumeni syndrome		DOID:3012	OMIM:PS151623	J:95318

Genotype
MGI:3722619

ht3

• Allelic Composition: Trp53^tm1Tyj/Trp53^tm3.1Glo
• Genetic Background: involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6

mortality/aging

premature death ( J:95318 )

• mice do not survive past 300 days compared to Trp53^tm1Tyj heterozygotes and Trp53^tm3.1Glo heterozygotes that live to 900 days

Genotype
MGI:5000508

ht4

• Allelic Composition: Trp53^tm3.1Glo/Trp53^tm4Glo
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

mortality/aging

decreased tumor-free survival time ( J:171821 )

• median survival is 160 days due to tumor development

neoplasm

abnormal tumor morphology ( J:171821 )

• tumors exhibit interstitial inflammatory cells unlike in tumors from Trp53^tm3.1Glo/Trp53^tm4Glo Tg(CAG-cre/Esr1*)5Amc mice

increased lymphoma incidence ( J:171821 )

• in 60% of mice (including T cell, diffuse, and large cell)

increased adenocarcinoma incidence ( J:171821 )

• in 4% of mice

increased spindle cell carcinoma incidence ( J:171821 )

increased sarcoma incidence ( J:171821 )

• in 37% of mice (including angiosarcoma, spindle-cell, and giant-cell)

Genotype
MGI:5000509

cn5

• Allelic Composition: Trp53^tm3.1Glo/Trp53^tm4Glo; Tg(CAG-cre/Esr1*)5Amc/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6 * CBA

mortality/aging

extended life span ( J:171821 )

• tamoxifen-treated mice survive longer than Trp53^tm3.1Glo/Trp53^tm4Glo mice

neoplasm

abnormal tumor pathology ( J:171821 )

• tamoxifen-treated lymphomas exhibit increased apoptosis response compared with tumors from Trp53^tm1Glo/Trp53^tm4Glo Tg(CAG-cre/Esr1*)5Amc mice

• 3 of 5 tamoxifen-treated lymphomas exhibit senescence unlike in tumors from Trp53^tm1Glo/Trp53^tm4Glo Tg(CAG-cre/Esr1*)5Amc mice

• tamoxifen-treated angiosarcomas and lymphomas exhibit senescence

decreased tumor growth/size ( J:171821 )

• tamoxifen-treated mice exhibit little to no tumor growth unlike in control mice

Genotype
MGI:7485800

cx6

• Allelic Composition: Pml^tm1Ppp/Pml⁺; Trp53^tm3.1Glo/Trp53^tm3.1Glo
• Genetic Background: B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo

mortality/aging

premature death ( J:317504 )

♂ • mean survival of male mice is 150 days, i.e., not significantly different from that in males homozygous for Trp53^tm3.1Glo alone (164.5 days)

prenatal lethality, incomplete penetrance ( J:317504 )

♀ • only 12% of females are born, indicating a severe reduction in female survival

Genotype
MGI:7485838

cx7

• Allelic Composition: Pml^tm1Ppp/Pml^tm1Ppp; Trp53^tm3.1Glo/Trp53⁺
• Genetic Background: B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo

mortality/aging

decreased tumor-free survival time ( J:317504 , J:317504 )

• median survival for the combined population of both males and females is 448 days, i.e., ~50 days shorter than in mice heterozygous for Trp53 ^tm3.1Glo alone (499 days) and in mice heterozygous for both Trp53 ^tm3.1Glo and Pml^tm1Ppp (504 days) (J:317504)

♂ • strikingly, median survival is 414 days for male mice, i.e., >100 days shorter than in males heterozygous for Trp53 ^tm3.1Glo alone (515 days) and in males heterozygous for both Trp53 ^tm3.1Glo and Pml^tm1Ppp (539 days) (J:317504)

♂ • average survival of male mice with soft tissue sarcomas (44%) is 380 days, i.e., even shorter than in males heterozygous for both Trp53 ^tm3.1Glo and Pml^tm1Ppp (443 days) which develop soft tissue sarcomas with a similar frequency (42%) (J:317504)

♂ • however, median survival for female mice is 485 days, i.e., not significantly different from that in males heterozygous for Trp53 ^tm3.1Glo alone (515 days) (J:317504)

neoplasm

increased lymphoma incidence ( J:317504 )

• 36% of mice develop lymphomas (when expressed as a % of tumor type); 18% of mice develop two tumor types, lymphomas and sarcomas

• 44% of mice exhibit lymphomas when tumor incidence is evaluated per mouse and expressed as a % disease/total number of mice

• when tumors are segregated by gender, 44% of males and 44% of females exhibit lymphomas (expressed as a % disease/total number of mice)

increased T cell derived lymphoma incidence ( J:317504 )

• ~40% of lymphoid tumors are T-cell lymphomas

increased B cell derived lymphoma incidence ( J:317504 )

• immunophenotyping of lymphocytes from terminally resected tumors showed that ~60% of lymphoid tumors are B-cell lymphomas

increased carcinoma incidence ( J:317504 , J:317504 )

• 5% of mice develop carcinomas (when expressed as a % of tumor type) (J:317504)

• 6% of mice exhibit carcinomas (when expressed as a % disease/total number of mice) (J:317504)

♀ • when tumors are segregated by gender, 0% of males and 11% of females exhibit carcinomas (expressed as a % disease/total number of mice) (J:317504)

increased sarcoma incidence ( J:317504 )

• 59% of mice develop sarcomas (when expressed as a % of tumor type); 18% of mice develop two tumor types, lymphomas and sarcomas

• 72% of mice exhibit sarcomas (when expressed as a % disease/total number of mice)

• when tumors are segregated by gender, 44% of males and 11% of females exhibit soft-tissue sarcomas (expressed as a % disease/total number of mice), indicating that males lacking PML succumb to aggressive soft tissue sarcomas more frequently than females

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by gender, 33% of males and 56% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

• although osteosarcomas are proportionately more abundant in female mice, survival latency is not significantly altered

immune system

increased T cell derived lymphoma incidence ( J:317504 )

• ~40% of lymphoid tumors are T-cell lymphomas

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 ^tm3.1Glo alone

liver/biliary system

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 ^tm3.1Glo alone

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:317504 )

• ~40% of lymphoid tumors are T-cell lymphomas

skeleton

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by gender, 33% of males and 56% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

• although osteosarcomas are proportionately more abundant in female mice, survival latency is not significantly altered

hematopoietic system

hematopoietic system phenotype ( J:317504 )

N • zero of 18 mice (0%) exhibit extramedullary hematopoiesis (EMH)

N • when segregated by gender, neither male nor female mice exhibit EMH

increased T cell derived lymphoma incidence ( J:317504 )

• ~40% of lymphoid tumors are T-cell lymphomas

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 ^tm3.1Glo alone

growth/size/body

growth/size/body region phenotype ( J:317504 )

N • average body weight is not significantly different from that in C57BL/6 wild-type controls

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 ^tm3.1Glo alone

Genotype
MGI:7485831

cx8

• Allelic Composition: Pml^tm1Ppp/Pml⁺; Trp53^tm3.1Glo/Trp53⁺
• Genetic Background: B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo

mortality/aging

premature death ( J:317504 )

• median survival for the combined population of both males and females is 504 days, i.e., similar to that of mice heterozygous for Trp53 ^tm3.1Glo alone (499 days)

• median survival is 539 days for male mice and 488 days for female mice, indicating that loss of a single Pml allele does not reduce the mean survival of either male or female Trp53 ^tm3.1Glo heterozygotes

decreased tumor-free survival time ( J:317504 )

♂ • average survival of male mice that present with soft tissue sarcomas (42%) is 443 days

neoplasm

increased lymphoma incidence ( J:317504 )

• 43% of mice develop lymphomas (when expressed as a % of tumor type); 14% of mice develop two tumor types, lymphomas and sarcomas

• 38% of mice exhibit lymphomas when tumor incidence is evaluated per mouse, including those that succumb to EMH, and expressed as a % disease/total number of mice

• when tumors are segregated by gender, 33% of males and 42% of females exhibit lymphomas (expressed as a % disease/total number of mice)

increased T cell derived lymphoma incidence ( J:317504 )

• ~20% of lymphoid tumors are T-cell lymphomas

increased B cell derived lymphoma incidence ( J:317504 )

• immunophenotyping of lymphocytes from terminally resected tumors showed that ~80% of lymphoid tumors are B-cell lymphomas

increased carcinoma incidence ( J:317504 , J:317504 )

• 5% of mice develop carcinomas (when expressed as a % of tumor type) (J:317504)

• 4% of mice exhibit carcinomas (when expressed as a % disease/total number of mice) (J:317504)

♀ • when tumors are segregated by gender, 0% of males and 8% of females exhibit carcinomas (expressed as a % disease/total number of mice) (J:317504)

increased sarcoma incidence ( J:317504 )

• 52% of mice develop sarcomas (when expressed as a % of tumor type); 14% of mice develop two tumor types, lymphomas and sarcomas

• 46% of mice exhibit sarcomas (when expressed as a % disease/total number of mice)

• when tumors are segregated by gender, 42% of males and 17% of females exhibit soft-tissue sarcomas (expressed as a % disease/total number of mice)

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by gender, 8% of males and 25% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

hematopoietic system

increased T cell derived lymphoma incidence ( J:317504 )

• ~20% of lymphoid tumors are T-cell lymphomas

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 ^tm3.1Glo alone

extramedullary hematopoiesis ( J:317504 )

• 33% mice exhibit extramedullary hematopoiesis (EMH)

• when segregated by gender, 33% of males and 33% of females exhibit EMH

immune system

increased T cell derived lymphoma incidence ( J:317504 )

• ~20% of lymphoid tumors are T-cell lymphomas

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 ^tm3.1Glo alone

liver/biliary system

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 ^tm3.1Glo alone

growth/size/body

decreased body weight ( J:317504 )

• average body weight is significantly lower than that in C57BL/6 wild-type controls

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 ^tm3.1Glo alone

skeleton

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by gender, 8% of males and 25% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:317504 )

• ~20% of lymphoid tumors are T-cell lymphomas

Genotype
MGI:7485803

cx9

• Allelic Composition: Pml^tm1Ppp/Pml^tm1Ppp; Trp53^tm3.1Glo/Trp53^tm3.1Glo
• Genetic Background: B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo

mortality/aging

premature death ( J:317504 )

♂ • mean survival of male mice is 156.5 days i.e., not significantly different from that in males homozygous for Trp53^tm3.1Glo alone (164.5 days)

prenatal lethality, incomplete penetrance ( J:317504 )

♀ • only 9% of females are born, indicating a severe reduction in female survival

Genotype
MGI:4835498

cx10

• Allelic Composition: Mdm2^tm3.1Glo/Mdm2^tm3.1Glo; Trp53^tm3.1Glo/Trp53⁺
• Genetic Background: B6.129S-Mdm2^tm3.1Glo Trp53^tm3.1Glo

mortality/aging

premature death ( J:164201 )

• overall survival is reduced relative to mice homozygous for Mdm2^tm4.1Glo and heterozygous for Trp53 ^tm3.1Glo

cellular

decreased cellular sensitivity to ionizing radiation ( J:164201 )

• in the thymus following a low dose of IR radiation compared to mice homozygous for Mdm2^tm4.1Glo and heterozygous for Trp53^tm3.1Glo

neoplasm

increased tumor incidence ( J:164201 )

• accelerated tumor onset relative to mice homozygous for Mdm2^tm4.1Glo and heterozygous for Trp53 ^tm3.1Glo

• the tumor spectrum is also altered relative to mice homozygous for Mdm2^tm4.1Glo and heterozygous for Trp53 ^tm3.1Glo

• mice develop multiple primary tumors

increased liver adenoma incidence ( J:164201 )

• in 1 mouse

increased lung adenoma incidence ( J:164201 )

• in 1 mouse

increased lipoma incidence ( J:164201 )

increased lymphoma incidence ( J:164201 )

increased histiocytic sarcoma incidence ( J:164201 )

increased carcinoma incidence ( J:164201 )

• salivary carcinoma in 1 mouse

• undefined carcinomas are also reported

increased adenocarcinoma incidence ( J:164201 )

increased mammary adenocarcinoma incidence ( J:164201 )

increased liver adenocarcinoma incidence ( J:164201 )

• in 1 mouse

increased squamous cell carcinoma incidence ( J:164201 )

increased sarcoma incidence ( J:164201 )

• soft tissue sarcoma

• chondrosarcoma in 1 mouse

increased leiomyosarcoma incidence ( J:164201 )

• in 1 mouse

increased fibrosarcoma incidence ( J:164201 )

increased hemangiosarcoma incidence ( J:164201 )

• ovarian

increased osteosarcoma incidence ( J:164201 )

increased papilloma incidence ( J:164201 )

• squamous cell papilloma in 1 mouse

muscle

increased leiomyosarcoma incidence ( J:164201 )

• in 1 mouse

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:164201 )

integument

increased mammary adenocarcinoma incidence ( J:164201 )

skeleton

increased osteosarcoma incidence ( J:164201 )

liver/biliary system

increased liver adenocarcinoma incidence ( J:164201 )

• in 1 mouse

increased liver adenoma incidence ( J:164201 )

• in 1 mouse

respiratory system

increased lung adenoma incidence ( J:164201 )

• in 1 mouse

Genotype
MGI:4835500

cx11

• Allelic Composition: Mdm2^tm4.1Glo/Mdm2^tm4.1Glo; Trp53^tm3.1Glo/Trp53⁺
• Genetic Background: B6.129S-Mdm2^tm4.1Glo Trp53^tm3.1Glo

neoplasm

increased lymphoma incidence ( J:164201 )

• in 1 mouse

increased histiocytic sarcoma incidence ( J:164201 )

increased carcinoma incidence ( J:164201 )

• an undefined carcinoma is reported in 1 mouse

increased adenocarcinoma incidence ( J:164201 )

• undefined adenocarcinomas are reported

increased liver adenocarcinoma incidence ( J:164201 )

increased squamous cell carcinoma incidence ( J:164201 )

• in 1 mouse

increased sarcoma incidence ( J:164201 )

• soft tissue sarcoma

increased fibrosarcoma incidence ( J:164201 )

increased osteosarcoma incidence ( J:164201 )

skeleton

increased osteosarcoma incidence ( J:164201 )

liver/biliary system

increased liver adenocarcinoma incidence ( J:164201 )

Genotype
MGI:5142303

cx12

• Allelic Composition: Mdm4^tm3.1Glo/Mdm4^tm3.1Glo; Trp53^tm3.1Glo/Trp53^tm3.1Glo
• Genetic Background: involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N

mortality/aging

mortality/aging ( J:174368 )

N • unlike mice homozygous the Mdm4 allele alone, double mutant mice are viable

Genotype
MGI:5000504

cx13

• Allelic Composition: Mdm2^tm1Glo/Mdm2^tm1Glo; Trp53^tm3.1Glo/Trp53^tm4Glo
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

mortality/aging

mortality/aging ( J:171821 )

N • lethality observed in Mdm2^tm1Glo homozygotes is completely rescued with mice surviving beyond 5 weeks

Genotype
MGI:3576494

cx14

• Allelic Composition: Mdm2^tm1Glo/Mdm2^tm1Glo; Trp53^tm3.1Glo/Trp53⁺
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

mortality/aging

prenatal lethality, complete penetrance ( J:95318 )

• no newborn mice are recovered